The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer

Gynecologic Oncology

Volumn 114, Issue 2, 2009, Pages 242-245

  Rocconi, Rodney P ^a   Matthews, Kellie S ^b   Kemper, Meredith K ^b   Hoskins, Kelly E ^b   Huh, Warner K ^b   Straughn Jr , J Michael ^b  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

CA 125; Chemotherapy; Ovarian Cancer; Platinum sensitivity; Survival

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; TAXANE DERIVATIVE;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; SURVIVAL RATE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CA-125 ANTIGEN; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; EPITHELIAL CELLS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 67549131967     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.04.019     Document Type: Article

References (9)

1. Eisenhauer E.A., Vermorken J.B., and van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann. Oncol. 8 (1997) 963-968
2. Ozols R.F. Treatment of recurrent ovarian cancer: increasing options-"recurrent" results. J. Clin. Oncol. 15 (1997) 2177-2180
3. Parmar M.K., Ledermann J.A., Colombo N., du Bois A., Delaloye J.F., Kristensen G.B., et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361 (2003) 2099-2106
4. Juretzka M.M., Barakat R.R., Chi D.S., Iasonos A., Dupont J., Abu-Rustum N.R., et al. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol. Oncol. 104 (2007) 176-180
5. Markman M., Liu P.Y., Rothenberg M.L., Monk B.J., Brady M., and Alberts D.S. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J. Clin. Oncol. 24 (2006) 1454-1458
6. Liu P.Y., Alberts D.S., Monk B.J., Brady M., Moon J., and Markman M. An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. J. Clin. Oncol. 25 (2007) 3615-3620
7. Crawford S.M., and Peace J. Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?. Ann. Oncol. 16 (2005) 47-50
8. Prat A., Parera M., Peralta S., Perez-Benavente M.A., Garcia A., Gil-Moreno A., et al. Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer. Ann. Oncol. 19 (2008) 327-331
9. Markman M., Federico M., Liu P.Y., Hannigan E., and Alberts D. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer. Gynecol. Oncol. 103 (2006) 195-198